etodolac has been researched along with B-Cell Chronic Lymphocytic Leukemia in 6 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "R-etodolac is a novel pro-apoptotic agent with potential antitumor activity against B-cell chronic lymphocytic leukemia (B-CLL)." | 9.13 | Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. ( Engert, A; Jensen, M; Kimby, E; Knauf, W; Oliff, IA; Osterborg, A; Poynton, C; Rummel, MJ; Weissinger, F, 2008) |
| "R-etodolac (SDX-101) is an isoform of the non-steroidal anti-inflammatory drug, etodolac, and is currently being tested in phase II clinical trials for the treatment of refractory B-cell chronic lymphocytic leukemia (B-CLL)." | 7.73 | Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. ( Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P, 2006) |
| "R-etodolac is a novel pro-apoptotic agent with potential antitumor activity against B-cell chronic lymphocytic leukemia (B-CLL)." | 5.13 | Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. ( Engert, A; Jensen, M; Kimby, E; Knauf, W; Oliff, IA; Osterborg, A; Poynton, C; Rummel, MJ; Weissinger, F, 2008) |
| "R-etodolac (SDX-101) is an isoform of the non-steroidal anti-inflammatory drug, etodolac, and is currently being tested in phase II clinical trials for the treatment of refractory B-cell chronic lymphocytic leukemia (B-CLL)." | 3.73 | Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. ( Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasui, H | 1 |
| Hideshima, T | 1 |
| Anderson, KC | 1 |
| Robak, P | 1 |
| Linke, A | 1 |
| Cebula, B | 1 |
| Robak, T | 1 |
| Smolewski, P | 1 |
| Lindhagen, E | 1 |
| Nissle, S | 1 |
| Leoni, L | 1 |
| Elliott, G | 2 |
| Chao, Q | 1 |
| Larsson, R | 1 |
| Aleskog, A | 1 |
| Lentzsch, S | 1 |
| Roodman, GD | 1 |
| Jensen, M | 1 |
| Engert, A | 1 |
| Weissinger, F | 1 |
| Knauf, W | 1 |
| Kimby, E | 1 |
| Poynton, C | 1 |
| Oliff, IA | 1 |
| Rummel, MJ | 1 |
| Osterborg, A | 1 |
| Nardella, FA | 1 |
| LeFevre, JA | 1 |
1 review available for etodolac and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Etodolac; Hematologic Neoplasms; Het | 2007 |
1 trial available for etodolac and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antineoplastic Agents; Apoptosis; Dose-Resp | 2008 |
4 other studies available for etodolac and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticarcinogenic Agents; Antineopla | 2006 |
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal | 2006 |
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chlorambu | 2007 |
Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Female; Humans; Immunophenotyping; Leukemia, Lymp | 2002 |